tetramethylpyrazine has been researched along with Cancer of Prostate in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (66.67) | 24.3611 |
| 2020's | 1 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Ji, Z; Li, H; Yan, W; Yu, X; Zhou, Y; Zhou, Z | 1 |
| Ji, Z; Li, H; Xiao, Y; Yan, W; Zhou, Y; Zhou, Z | 1 |
| Guo, W; Han, J; He, X; Huang, H; Li, X; Li, Y; Liu, X; Song, J; Wang, S; Xing, W; Xu, X; Zhao, R; Zhu, M | 1 |
3 other study(ies) available for tetramethylpyrazine and Cancer of Prostate
| Article | Year |
|---|---|
Tetramethylpyrazine reduces prostate cancer malignancy through inactivation of the DPP10‑AS1/CBP/FOXM1 signaling pathway.
Topics: Adult; Aged; Animals; Antineoplastic Agents, Phytogenic; Apoptosis; Biopsy; Cell Line, Tumor; Cell Survival; CREB-Binding Protein; Forkhead Box Protein M1; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; Humans; Male; Mice; Middle Aged; Prostate; Prostatic Neoplasms; Pyrazines; RNA, Long Noncoding; Signal Transduction; Up-Regulation; Xenograft Model Antitumor Assays | 2020 |
Tetramethylpyrazine inhibits prostate cancer progression by downregulation of forkhead box M1.
Topics: Cell Line, Tumor; Cell Movement; Cell Proliferation; Forkhead Box Protein M1; Gene Expression Regulation, Neoplastic; Humans; Male; Neoplasm Invasiveness; Prostatic Neoplasms; Pyrazines | 2017 |
Ligustrazine Suppresses the Growth of HRPC Cells through the Inhibition of Cap- Dependent Translation Via Both the mTOR and the MEK/ERK Pathways.
Topics: Apoptosis; Cell Line, Tumor; Cell Proliferation; Eukaryotic Initiation Factor-4E; Humans; Male; MAP Kinase Signaling System; Phosphorylation; Prostatic Neoplasms; Protein Biosynthesis; Pyrazines; Signal Transduction; TOR Serine-Threonine Kinases | 2015 |